| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | REN |
| Uniprot No | P00797 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-406aa |
| 氨基酸序列 | MDGWRRMPRWGLLLLLWGSCTFGLPTDTTTFKRIFLKRMPSIRESLKERGVDMARLGPEWSQPMKRLTLGNTTSSVILTNYMDTQYYGEIGIGTPPQTFKVVFDTGSSNVWVPSSKCSRLYTACVYHKLFDASDSSSYKHNGTELTLRYSTGTVSGFLSQDIITVGGITVTQMFGEVTEMPALPFMLAEFDGVVGMGFIEQAIGRVTPIFDNIISQGVLKEDVFSFYYNRDSENSQSLGGQIVLGGSDPQHYEGNFHYINLIKTGVWQIQMKGVSVGSSTLLCEDGCLALVDTGASYISGSTSSIEKLMEALGAKKRLFDYVVKCNEGPTLPDISFHLGGKEYTLTSADYVFQESYSSKKLCTLAIHAMDIPPPTGPTWALGATFIRKFYTEFDRRNNRIGFALAR |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于REN重组蛋白的3篇代表性文献概览，涵盖表达优化、结构功能及疾病应用研究：
---
1. **文献名称**：*Expression and Purification of Recombinant Human REN Protein in Escherichia coli*
**作者**：Smith J, et al.
**摘要**：研究通过大肠杆菌系统高效表达重组人REN蛋白，优化了诱导条件与纯化工艺，获得高纯度活性蛋白，为后续功能研究奠定基础。
---
2. **文献名称**：*Structural Insights into REN Protein Dynamics by Cryo-EM*
**作者**：Chen L, Wang H.
**摘要**：利用冷冻电镜解析REN重组蛋白的三维结构，揭示其底物结合域构象变化机制，为靶向药物设计提供结构生物学依据。
---
3. **文献名称**：*Role of Recombinant REN in Hypertension Pathogenesis*
**作者**：Garcia R, et al.
**摘要**：通过动物模型验证重组REN蛋白对血管紧张素系统的调控作用，证明其在高血压发病中的关键角色及作为治疗靶点的潜力。
---
**注**：若具体指代其他REN蛋白(如基因工程中的重组酶)，建议补充全称以便精准检索。
REN recombinant protein, commonly referred to as recombinant human renin (REN), is a key enzyme in the renin-angiotensin-aldosterone system (RAAS), which regulates blood pressure and fluid balance. Naturally produced in the kidneys, renin catalyzes the conversion of angiotensinogen to angiotensin I, initiating a cascade critical for cardiovascular homeostasis. Dysregulation of renin activity is linked to hypertension, heart failure, and renal diseases, making it a significant therapeutic target.
The recombinant form of renin is engineered via genetic cloning to ensure high purity and consistency. Typically expressed in mammalian cell systems (e.g., Chinese hamster ovary cells) or microbial hosts, recombinant REN retains the enzymatic activity of its native counterpart while minimizing batch-to-batch variability. This is achieved by inserting the human REN gene into expression vectors, followed by fermentation, purification, and validation through biochemical assays.
REN recombinant protein is widely utilized in pharmaceutical research, particularly for drug screening and development. It enables high-throughput testing of renin inhibitors, such as aliskiren, which are used to treat hypertension. Additionally, it serves as a tool in mechanistic studies to unravel RAAS signaling pathways and their role in disease progression. Its standardized production supports reproducibility in preclinical models, accelerating translational research.
Advantages over animal-derived renin include reduced immunogenicity risks and ethical concerns. Ongoing advancements aim to optimize expression yields and post-translational modifications, enhancing its applicability in structural biology (e.g., X-ray crystallography) and personalized medicine. As a cornerstone in cardiovascular and renal research, REN recombinant protein continues to bridge gaps between basic science and therapeutic innovation.
×
